Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL
03:30pm, Monday, 06'th Feb 2023 Zacks Investment Research
Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.
3 No-Brainer Stocks to Buy Right Now for Less Than $25
02:40pm, Saturday, 04'th Feb 2023 The Motley Fool
All three healthcare stocks are showing solid long-term potential.
3 No-Brainer Stocks to Buy Right Now for Less Than $25
09:40am, Saturday, 04'th Feb 2023
All three healthcare stocks are showing solid long-term potential.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
03:00pm, Tuesday, 31'st Jan 2023 Zacks Investment Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
11:45am, Tuesday, 31'st Jan 2023
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
03:00pm, Thursday, 26'th Jan 2023 Benzinga
Upgrades
According to Tigress Financial, the prior rating for Walmart Inc (NYSE:WMT) was changed from Neutral to Buy. In the third quarter, Walmart showed an EPS of $1.50, compared to $1.45 from the y
Exelixis' Patent Decision In Line With Expectations, But Analysts Say Stock Overhang Could Continue
06:17pm, Friday, 20'th Jan 2023 Benzinga
Exelixis Inc (NASDAQ: EXEL) announced that the U.S. District Court for the District of Delaware ruled in its favor, rejecting MSN Laboratories Private Limited's challenge to the cabozantinib compo
Exelixis: Building On A Blockbuster
07:24pm, Wednesday, 18'th Jan 2023
Exelixis' CABOMETYX is hitting on all cylinders. Exelixis has an interesting and highly cabozantinib-centric pipeline.
7 Biotech Stocks That Will Make You Rich in 10 Years
03:44pm, Wednesday, 18'th Jan 2023
If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they'r
6 Analysts Have This to Say About Exelixis
01:00pm, Wednesday, 11'th Jan 2023 Benzinga
Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
3
1
0
0
Last 30D
1
0
Strength Seen in Harmony Biosciences Holdings, Inc. (HRMY): Can Its 5.1% Jump Turn into More Strength?
12:56pm, Wednesday, 11'th Jan 2023 Zacks Investment Research
Harmony Biosciences Holdings, Inc. (HRMY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest fu
Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results
06:33pm, Monday, 09'th Jan 2023 Zacks Investment Research
Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.
Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results
03:03pm, Monday, 09'th Jan 2023
Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.
Four Undervalued Healthcare Stocks for 2023
11:21am, Friday, 06'th Jan 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
ALAMEDA, Calif.--( BUSINESS WIRE )--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overvi
